{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'Systemic', 'Mild (Grade 1)', 'Moderate (Grade 2)', 'Severe (Grade 3)', 'Noticeable with no', 'Completely unable to', 'Nausea', 'limitation in normal daily', 'Some limitation in', 'perform normal daily', 'activity', 'normal daily activity', 'activity', 'Noticeable with no', 'Some limitation in', 'Completely unable to', 'Vomiting', 'limitation in normal daily', 'normal daily activity', 'perform normal daily', 'activity', 'activity', 'Noticeable with no', 'Completely unable to', 'Diarrhea', 'limitation in normal daily', 'Some limitation in', 'perform normal daily', 'activity', 'normal daily activity', 'activity', 'Noticeable with no', 'Completely unable to', 'Headache', 'limitation in normal daily', 'Some limitation in', 'perform normal daily', 'activity', 'normal daily activity', 'activity', 'Table 4 Unsolicited Adverse Events', 'Systemic Illness', 'Mild (Grade 1)', 'Moderate (Grade 2)', 'Severe (Grade 3)', 'Noticeable with no', 'Completely unable to', 'Illness or clinical', 'Some limitation in', 'limitation in normal daily', 'perform normal daily', 'adverse event', 'activity', 'normal daily activity', 'activity', 'We will monitor study participants for the development of new onset acute or chronic medical', 'conditions during the protocol-defined surveillance period of 42 days post-vaccination. These', 'AEs will be reviewed periodically by a safety monitoring panel (Section 5.4.3). We will monitor', 'study participants for SAEs during the protocol-defined surveillance period of 42 days post-', 'vaccination and up to 181 days for the longer-term immunogenicity subset (Section 5.4.2).', '5.4.1.1', 'Adverse events of clinical interest', 'We will also collect information regarding the occurrence of any adverse events of clinical', 'interest. Events of clinical interest include syncope during post-vaccination monitoring in clinic,', 'anaphylaxis in the first 24 hours after immunization, and new onset immune-mediated disease', 'as defined in Appendix G.', '5.4.1.2', 'Causality (relatedness) Assessment', 'Study site investigators will assess relatedness to vaccine or study procedures (related, possibly', 'related, unlikely related, or not related) for SAEs, AEs, and AEs of clinical interest. Relatedness', 'determinations of these events will inform IRB reporting and safety monitoring (Section 5.4.3).', 'Solicited symptoms in Table 3 will all be considered to be related to vaccine and causality', 'assessment will not be done for these events. The study investigators will use their clinical', 'judgement to make causality assessments and may consult the Expert Safety Panel or CISA', 'Project for assistance with causality determinations. The final causality assessment decision is', 'the responsibility of the site PI where the subject was enrolled.', '26']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', '5.4.2 Reporting of Adverse Events', 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation', 'subject administered a pharmaceutical product and which does not necessarily have to have a', 'causal relationship with this treatment.', 'If indicated, AEs occurring during the study will be reported to the Vaccine Adverse Event', 'Reporting System (VAERS). The National Childhood Vaccine Injury Act requires healthcare', 'providers to report the following AEs to VAERS:', 'Any adverse event listed by the vaccine manufacturer as a contraindication to further', 'doses of the vaccine; or', 'Any adverse event listed in the VAERS Table of Reportable Events Following', 'Vaccination [PDF - 75KB] that occurs within the specified time period after vaccination.', 'In addition, CDC encourages reporting of any clinically significant adverse event that occurs in a', 'patient following a vaccination, even if there is uncertainty regarding if a vaccine caused the', 'event.', 'A serious adverse event (SAE) is defined as an AE that meets one of the following conditions24:', 'Results in death', 'Is life-threatening (defined as immediate risk of death at the time of the event)', 'Requires inpatient hospitalization (initial or prolonged)', 'Results in a persistent or significant disability/incapacity', 'Any other important medical event that may not result in death, be life threatening, or require', 'hospitalization, may be considered an SAE when, based upon appropriate medical judgment,', 'the event may jeopardize the subject and may require medical or surgical intervention to', 'prevent one of the outcomes listed above.', 'SAE and AE reporting will occur consistent with institutional policy. The original verbatim terms', 'used by investigators to identify SAEs and adverse events of clinical interest in the case report', 'form will be mapped to preferred terms using the Medical Dictionary for Regulatory Activities', '(MedDRA) dictionary (http://www.meddra.org/).', 'Vaccine-related SAEs will be medically attended per routine care', 'SAEs will be reported promptly to the overseeing IRBs in accordance with institutional', 'procedures. Any unanticipated problems resulting from study conduct related to participation will', 'be reported promptly to the reviewing IRBs and CDC, in accordance with institutional', 'procedures.', \"The duration of subject's participation in the study varies based on their involvement in the\", 'immunogenicity sub-study. Therefore, the period for monitoring and reporting SAEs varies', 'among subjects as shown below:', '27']\n\n###\n\n", "completion": "END"}